TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing

References

• Ravi P, Kumar SK, Cerhan JR, Maurer MJ, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8(3):26.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346–1348.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• Ho PJ, Moore EM, McQuilten ZK, et al. Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand myeloma and related diseases registry. Clin Lymphoma Myeloma Leuk. 2019;19(8):e415–e424.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126(3):300–310.
   PubMed Web of Science ®Google Scholar
• Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol. 2017;44(6):377–380.
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–6391.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Ruschak AM, Slassi M, Kay LE, et al. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103(13):1007–1017.
   PubMedGoogle Scholar
• Kalff A, Khong T, Wall M, et al. A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Haematologica. 2015;100(2):e60–e62.
   PubMed Web of Science ®Google Scholar
• Gong J-N, Khong T, Segal D, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128(14):1834–1844.
   PubMed Web of Science ®Google Scholar
• Mithraprabhu S, Khong T, Spencer A. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. Cell Death Dis. 2014;5(3):e1134.
   PubMedGoogle Scholar
• Savvidou I, Khong T, Cuddihy A, et al. β-Catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma. Mol Cancer Ther. 2017;16(9):1765–1778.
   PubMed Web of Science ®Google Scholar
• Chen T, Sun Y, Ji P, et al. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 2015;34(31):4019–4031.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9(5):338–350.
   PubMed Web of Science ®Google Scholar
• Besse A, Besse L, Kraus M, et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019;26(3):340–351.e3.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574–582.
   PubMed Web of Science ®Google Scholar
• Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget. 2015;6(17):14814–14831.
   PubMedGoogle Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020–2028.
   PubMed Web of Science ®Google Scholar
• Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543–2553.
   PubMed Web of Science ®Google Scholar
• Kuiper R, van Duin M, van Vliet MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126(17):1996–2004.
   PubMed Web of Science ®Google Scholar
• Liu X-P, Yin X-H, Meng X-Y, et al. Development and validation of a 9-gene prognostic signature in patients with multiple myeloma. Front Oncol. 2018;8:615.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Li X, Yang Y, et al. Cell cycle-dependent gene networks relevant to cancer. Prog Nat Sci. 2008;18(8):945–952.
   Web of Science ®Google Scholar
• Olszewski WT, Pieńkowski T, Olszewski WP, et al. Topoisomerase 2α status in invasive breast carcinoma – comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation. Pol J Pathol. 2014;4:283–290.
   Google Scholar
• Borazanci E, Millis SZ, Korn R, et al. Adenosquamous carcinoma of the pancreas: molecular characterization of 23 patients along with a literature review. World J Gastrointest Oncol. 2015;7(9):132–140.
   PubMed Web of Science ®Google Scholar
• Klintman M, Buus R, Cheang MCU, et al. Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer, and prognostic implications in residual disease. Clin Cancer Res. 2016;22(10):2405–2416.
   PubMed Web of Science ®Google Scholar
• Neubauer E, Wirtz RM, Kaemmerer D, et al. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: issues and prospects. Oncotarget. 2106;7(27):41959–41973.
   Google Scholar
• Wong N, Yeo W, Wong W-L, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124(3):644–652.
   PubMed Web of Science ®Google Scholar
• de Resende MF, Vieira S, Chinen LTD, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):36.
   PubMedGoogle Scholar
• Ma W, Wang B, Zhang Y, et al. Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis. Cancer Cell Int. 2019;19(1):1–17.
   PubMed Web of Science ®Google Scholar
• Pabla S, Conroy JM, Nesline MK, et al. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunotherapy Cancer. 2019;7(1):1–13.
   PubMed Web of Science ®Google Scholar
• Serna G, Ruiz-Pace F, Cecchi F, et al. Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Sci Rep. 2019;9(1):1–10.
   PubMedGoogle Scholar
• Erriquez J, Becco P, Olivero M, et al. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015;138(3):627–633.
   PubMed Web of Science ®Google Scholar
• Ghisoni E, Maggiorotto F, Borella F, et al. TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. J Ovarian Res. 2019;12(1):1–6.
   PubMedGoogle Scholar
• Gerrie AS, Mikhael JR, Cheng L, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013;161(6):802–810.
   PubMed Web of Science ®Google Scholar
• Green DJ, Bensinger WI, Holmberg LA, et al. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2016;51(10):1330–1336.
   PubMed Web of Science ®Google Scholar
• Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1):e272.
   PubMedGoogle Scholar
• Volkova M, Russel R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–220.
   PubMedGoogle Scholar
• Schaefer-Klein JL, Murphy SJ, Johnson SH, et al. Topoisomerase 2 alpha cooperates with androgen receptor to contribute to prostate cancer progression. PLoS One. 2015;10(11):e0142327.
   PubMed Web of Science ®Google Scholar
• Crawford LJ, Anderson G, Johnston CK, et al. Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget. 2016;7(43):70481–70493.
   PubMedGoogle Scholar
• Turner JG, Dawson JL, Grant S, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):1–11.
   PubMedGoogle Scholar
• von Metzler I, Heider U, Mieth M, et al. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp Cell Res. 2009;315(14):2471–2478.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19(8):522–530.e1.
   PubMed Web of Science ®Google Scholar